Massachusetts Financial Services Co. MA Sells 56,175 Shares of Qiagen (NYSE:QGEN)

Massachusetts Financial Services Co. MA reduced its position in Qiagen (NYSE:QGEN) by 0.2% in the second quarter, Holdings Channel.com reports. The fund owned 23,196,437 shares of the company’s stock after selling 56,175 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.10% of Qiagen worth $953,142,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of QGEN. Riverview Trust Co purchased a new position in shares of Qiagen during the first quarter worth about $28,000. Park Place Capital Corp purchased a new position in Qiagen in the 1st quarter worth approximately $36,000. Quarry LP bought a new position in shares of Qiagen in the 4th quarter worth $38,000. CWM LLC raised its position in shares of Qiagen by 19.1% during the 1st quarter. CWM LLC now owns 2,236 shares of the company’s stock valued at $96,000 after buying an additional 358 shares in the last quarter. Finally, Headlands Technologies LLC lifted its holdings in shares of Qiagen by 396.6% during the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after acquiring an additional 2,189 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on QGEN. Robert W. Baird increased their target price on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. increased their price objective on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, June 18th. Finally, Wolfe Research raised Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a report on Thursday, June 27th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.10.

Qiagen Price Performance

Shares of Qiagen stock opened at $46.36 on Monday. The stock has a market capitalization of $10.58 billion, a P/E ratio of 31.09, a price-to-earnings-growth ratio of 3.25 and a beta of 0.39. Qiagen has a one year low of $34.74 and a one year high of $47.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. The business’s 50 day simple moving average is $44.45 and its two-hundred day simple moving average is $43.40.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. The company had revenue of $496.00 million during the quarter, compared to analyst estimates of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm’s revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.53 EPS. Analysts forecast that Qiagen will post 2.15 EPS for the current year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.